Is Boston Beer on Watch for Activists?

by | May 26, 2023

Boardroom Alpha provides in-depth analytics and tracking of all public company executives and officers. Below is a rundown of people moves made at notable companies this past week. Get a demo today to see how you can receive real-time alerts and in-depth analytics.

Is Boston Beer on Watch for Activists?

Boardroom Alpha’s Activist Risk Score has highlighted Boston Beer Co. (SAM) as having an elevated risk of activist shareholder involvement vs. its peer set. The metric looks at several fundamental, governance and performance factors.

In the below blog we take a look at some of the potential red flags that make SAM more vulnerable to activist shareholders.

Boston Beer Co. (SAM) Faces an Elevated Risk of Activism

Lagging financials, performance and governance red flags pose a potential risk of an activist campaign relative to its peers.

Boston Beer’s Shares Have Underperformed

Shares are down ~40% over the last three years, trailing the broader equity market by a wide margin.

The Company Possesses Several Potential Red Governance Flags

Founder voting control, limited external board experience, and entrenched directors highlight a long list of potential governance red flags.

Founder Jim Koch Exerts Full Control

As the sole holder of Class B shares, Founder Jim Koch effectively appoints 6 of the 9 members of the board on an annual basis. In recent years Class A shareholders have expressed more displeasure in the board with very low support rates.

SAM’s Board is Entrenched and its Directors have Limited Outside Board Experience

Some Concern with CEO Pay for Performance

Insiders are Not Buying any Stock, and are Profiting from Sales

Recent Events – CFO Leaves

New Supply Chain Officer and the company also disclosed plans to purchase another $25M of stock.

Recent Analysis

CEO & CFO Moves Review – November 8, 2024

Explore last week’s CEO and CFO transitions at major public companies like Adial Pharmaceuticals, Affirm Holdings, Agrify Corp, and Dollar Tree. Learn about the new leaders taking charge amidst financial challenges, governance risks, and stock performance issues. This update covers executive shifts at companies facing shareholder pressures, regulatory scrutiny, and strategic reorganizations.

Daily SPAC Update – November 7, 2024

ACAB + Abpro SPAC Deal Vote. MCAA Extension Vote. FRLA and INTE Shareholders Extend. ROCL Deal and GLAC Extension Votes Set. ACAB Non-Redemption Agreement.

Subscribe to Boardroom Alpha Newsletters

Subscribe to Boardroom Alpha's research to receive the latest on governance, SPACs, and people.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.